1.Comparison of Clinical Efficacy between a Single Administration of Long-Acting Gonadotrophin-Releasing Hormone Agonist (GnRHa) and Daily Administrations of Short-Acting GnRHa in In Vitro Fertilization-Embryo Transfer Cycles.
Kang Woo CHEON ; Sang Jin SONG ; Bum Chae CHOI ; Seung Chul LEE ; Hong Bok LEE ; Seung Youn YU ; Keun Jai YOO
Journal of Korean Medical Science 2008;23(4):662-666
This study was aimed to evaluate the efficacy of a single administration of long-acting gonadotrophin-releasing hormone agonist (GnRHa) as compared with daily administrations of short-acting GnRHa in controlled ovarian hyperstimulation (COH) for in vitro fertilization and embryo transfer (IVF-ET) cycles. The mean dosage of recombinant follicle-stimulating hormone (rFSH) required for COH (2,354.5+/-244.2 vs. 2,012.5+/-626.1 IU) and the rFSH dosage per retrieved oocyte (336.7+/-230.4 vs. 292.1+/-540.4 IU) were significantly higher in the long-acting GnRHa group (N= 22) than those in the short-acting GnRHa group (N=28) (p<0.05). However, the mean number of visit to the hospital that was required before ovum pick-up (3.3+/-0.5 vs. 22.2+/-2.0) and the frequency of injecting GnRHa and rFSH (12.8+/-1.2 vs. 33.5+/- 3.5) were significantly decreased in the long-acting GnRHa group (p<0.0001). The clinical pregnancy rate, implantation rate, and early pregnancy loss rate were not significantly different between the 2 groups. So, we suggest that a single administration of long-acting GnRHa is a useful alternative for improving patient's convenience with clinical outcomes comparable to daily administrations of short-acting GnRHa in COH for IVF-ET cycles.
Adult
;
Buserelin/*therapeutic use
;
*Embryo Transfer
;
Female
;
*Fertilization in Vitro
;
Follicle Stimulating Hormone/therapeutic use
;
Goserelin/therapeutic use
;
Humans
;
Leuprolide/*therapeutic use
2.The current status of hormone treatment for prostate cancer patients in Korean real-world practice: a multi-institutional observational study.
Jung Kwon KIM ; Jung Jun KIM ; Taek Won GANG ; Tae Kyun KWON ; Hong Sup KIM ; Seung Chul PARK ; Jae-Shin PARK ; Jong-Yeon PARK ; Seok Joong YOON ; Youn-Soo JEON ; Jin Seon CHO ; Kwan Joong JOO ; Sung-Hoo HONG ; Seok-Soo BYUN
Asian Journal of Andrology 2019;21(2):115-120
We aimed to evaluate the current nationwide trend, efficacy, safety, and quality of life (QoL) profiles of hormone treatment in real-world practice settings for prostate cancer (PCa) patients in Korea. A total of 292 men with any biopsy-proven PCa (TanyNanyMany) from 12 institutions in Korea were included in this multi-institutional, observational study of prospectively collected data. All luteinizing hormone-releasing hormone (LHRH) agonists were allowed to be investigational drugs. Efficacy was defined as (1) the rate of castration (serum testosterone ≤50 ng dl-1) at 4-week visit and (2) breakthrough (serum testosterone >50 ng dl-1 after castration). Safety assessments included routine examinations for potential adverse events, laboratory tests, blood pressure, body weight, and bone mineral density (BMD, at baseline and at the last follow-up visit). QoL was assessed using the Expanded Prostate Cancer Index Composite-26 (EPIC-26). The most common initial therapeutic regimen was LHRH agonist with anti-androgen (78.0%), and the most commonly used LHRH agonist for combination and monotherapy was leuprolide (64.0% for combination and 58.0% for monotherapy). The castration and breakthrough rates were 78.4% and 6.6%, respectively. The laboratory results related to dyslipidemia worsened after 4 weeks of hormone treatment. In addition, the mean BMD T-score was significantly lower at the last follow-up (mean: -1.950) compared to baseline (mean: -0.195). The mean total EPIC-26 score decreased from 84.8 (standard deviation [s.d.]: 12.2) to 78.3 (s.d.: 8.1), with significant deterioration only in the urinary domain (mean: 23.5 at baseline and 21.9 at the 4-week visit). These findings demonstrate the nationwide trend of current practice settings in hormone treatment for PCa in Korea.
Aged
;
Androgen Antagonists/therapeutic use*
;
Antineoplastic Agents, Hormonal/therapeutic use*
;
Cholesterol/blood*
;
Drug Therapy, Combination
;
Humans
;
Leuprolide/therapeutic use*
;
Male
;
Middle Aged
;
Prostatic Neoplasms/pathology*
;
Quality of Life
;
Receptors, LHRH/agonists*
;
Republic of Korea
;
Testosterone/blood*
;
Treatment Outcome
;
Triglycerides/blood*
3.A Case of Mental Retardation with Paraphilia Treated with Depot Leuprorelin.
Woo Sung PARK ; Kyung Min KIM ; Yong Woo JUNG ; Myung Ho LIM
Journal of Korean Medical Science 2014;29(9):1320-1324
Paraphilia is a psychiatric disease that has been difficult to cure. However, recently developed therapeutic methods hold promise. The patient was a 20-yr-old male with chief complaints of continuous masturbation, genital exposure, and aggressive behavior that started 2 yr ago. We administered leuprorelin 3.6 mg intramuscular injection per month, a depot gonadotrophin-releasing hormone analogue, to this patient who a severe mentally retardation with paraphilia. The clinical global impression (CGI)-severity, CGI-improvement and aberrant behavior checklist were performed. After one month, we observed significant improvement in symptoms, such as decreases of abnormal sexual behavior and sexual desire. The GnRH analogues are suggested to be used as an alternative or supplementary therapeutic method for sexual offenders after clinical studies.
Humans
;
Leuprolide/pharmacology/*therapeutic use
;
Male
;
Mental Disorders/complications/diagnosis/*drug therapy
;
Paraphilias/complications/diagnosis/*drug therapy
;
Sex Offenses/prevention & control
;
Sexual Behavior/drug effects
;
Young Adult
4.Long-term effectiveness of luteinizing hormone-releasing hormone agonist or antiandrogen monotherapy in elderly men with localized prostate cancer (T1-2): a retrospective study.
Rupesh RAINA ; Geetu PAHALAJANI ; Ashok AGARWAL ; Craig ZIPPE
Asian Journal of Andrology 2007;9(2):253-258
AIMTo evaluate the long-term effectiveness, side effects and compliance rates of two types of drugs (luteinizing hormone-releasing hormone [LHRH] agonist and antiandrogen) that were used individually to treat patients with localized prostate cancer (T1-2) at our institution.
METHODSNinety-seven patients who were diagnosed in the period from April 1997 to January 2000 as having clinically localized prostate cancer (T1-2) received either LHRH agonist (leuprolide acetate 7.5 mg/month) monotherapy (group 1, n = 62) or antiandrogen monotherapy (group 2, n = 35; 18 received bicalutamide 50 mg q.d., 13 received nilutamide 150 mg t.i.d. and 4 received flutamide 250 mg t.i.d.). The mean age in both groups was 76 years.
RESULTSThe mean follow-up time was (50.8 +/- 8.5) months in group 1 and (43.1 +/- 2.2) months in group 2. Prostate-specific antigen (PSA) levels rose in only 1 of the 62 patients (1.6%) in group 1, and in 20 of the 35 patients (57.1%) in group 2. In group 2, 10 of the 20 patients (50%) with increasing PSA levels were treated with LHRH salvage therapy, and eight (80%) responded. Hot flashes (54.8%) and lethargy (41.9%) were the most common side effects in group 1. In contrast, nipple-tenderness (40%) and light-dark adaptation (17.1%) were more often seen in group 2. Only 1 of the 62 patients (1.6%) in group 1 switched to another medication because of adverse side effects; whereas 8 of the 35 patients (22.9%) in group 2 did so.
CONCLUSIONUnlike antiandrogen monotherapy, LHRH agonist monotherapy provided long-term durable control of localized prostate cancer (T1-2). It can also be an effective treatment option for patients whose disease failed to respond to antiandrogen monotherapy. The limitations of our study are the lack of health outcomes analysis and a small sample size.
Aged ; Aged, 80 and over ; Androgen Antagonists ; adverse effects ; therapeutic use ; Anilides ; adverse effects ; therapeutic use ; Flutamide ; adverse effects ; therapeutic use ; Gonadotropin-Releasing Hormone ; agonists ; Humans ; Imidazolidines ; adverse effects ; therapeutic use ; Leuprolide ; adverse effects ; therapeutic use ; Male ; Nitriles ; adverse effects ; therapeutic use ; Prostate-Specific Antigen ; blood ; Prostatic Neoplasms ; drug therapy ; Retrospective Studies ; Tosyl Compounds ; adverse effects ; therapeutic use
5.GnRH Agonist Therapy in a Patient with Recurrent Ovarian Granulosa Cell Tumors.
Hyun Jung KIM ; Sang Cheol LEE ; Sang Byung BAE ; Kye Won KWON ; Chan Kyu KIM ; Nam Su LEE ; Kyu Taek LEE ; Jong Ho WON ; Dae Sik HONG ; Hee Sook PARK
Journal of Korean Medical Science 2009;24(3):535-538
A 65-yr-old woman presented 17 yr status post-hysterectomy with bilateral ovarian salpingo-oophorectomy, attributable to ovarian cancer. She was admitted to our hospital, with multiple cystic liver masses and multiple large seeded masses in her abdomen and pelvic cavity. Histological examination of the pelvic masses demonstrated granulosa cell tumors. After two courses of systemic combination chemotherapy, with paclitaxel and carboplatin, the masses in the abdomen and pelvic cavity increased, and debulking surgery also failed because of peritoneal dissemination with severe adhesion. Finally, she underwent palliative radiotherapy for only the pelvic masses obstructing the urinary and GI tracts, and monthly hormonal therapy with a gonadotrophin-releasing hormone agonist; leuprorelin 3.75 mg IM. Subsequently, multiple masses beyond the range of the radiation as well as those within the radiotherapy field partially decreased. This partial response had been maintained for more than 8 months as of the last follow-up visit. Owing to its long and indolent course and the low metabolic rate of the tumors, advanced or recurrent granulosa cell tumor (GCT) requires treatment options beyond chemotherapy, surgery, and radiotherapy. Hormonal agents may provide another treatment option for advanced or recurrent GCT in those who are not candidates for surgery, chemotherapy, or radiotherapy.
Aged
;
Antineoplastic Agents, Hormonal/*therapeutic use
;
Female
;
Gonadotropin-Releasing Hormone/*agonists/metabolism
;
Granulosa Cell Tumor/diagnosis/*drug therapy/radiography
;
Humans
;
Leuprolide/*therapeutic use
;
Ovarian Neoplasms/diagnosis/*drug therapy/radiography
;
Recurrence
6.GnRH Agonist Therapy to Protect Ovarian Function in Young Korean Breast Cancer Patients.
Hyun Jung PARK ; Young Ah KOO ; Young Hyuck IM ; Byung Koo YOON ; DooSeok CHOI
Journal of Korean Medical Science 2010;25(1):110-116
The increased survival of patients with breast cancer has given rise to other problems associated with the complications of chemotherapy. One major complication is premature ovarian failure, an especially harmful outcome for women of reproductive age. This study was performed to evaluate the efficacy of GnRH agonist (GnRHa) treatment on protecting ovarian function in young breast cancer patients (30.59+/-5.1 yr) receiving chemotherapy after surgery. Twenty-two women were enrolled and given subcutaneous injections of leuprolide acetate (3.75 mg) every 4 weeks during chemotherapy. Follow-up laboratory tests (luteinizing hormone [LH], follicle stimulating hormone [FSH], and estradiol) were performed 1, 3, and 6 months after chemotherapy. Menstruation patterns and clinical symptoms were followed up for a mean duration of 35.6+/-1.7 months. FSH and LH levels were normal in all patients 6 months after completing chemotherapy (8.0+/-5.3, 4.4+/-2.7 mIU/mL, respectively). During follow-up, none of the patients complained of menopausal symptoms and 81.8% experienced recovery of menstruation. This report is the first trial of GnRHa as a treatment modality to protect ovarian function during adjuvant chemotherapy in young Korean breast cancer patients.
Adult
;
Antineoplastic Agents/adverse effects/therapeutic use
;
Antineoplastic Agents, Hormonal/therapeutic use
;
Breast Neoplasms/diagnosis/*drug therapy/surgery
;
Combined Modality Therapy
;
Cyclophosphamide/adverse effects/therapeutic use
;
Doxorubicin/adverse effects/therapeutic use
;
Female
;
Follicle Stimulating Hormone/analysis
;
Gonadotropin-Releasing Hormone/*agonists
;
Humans
;
Leuprolide/administration & dosage
;
Luteinizing Hormone/analysis
;
Menstruation
;
Ovarian Function Tests
;
Primary Ovarian Insufficiency/etiology/*prevention & control
;
Republic of Korea
;
Tamoxifen/therapeutic use
;
Time Factors
7.Efficacy and safety of domestic leuprorelin in girls with idiopathic central precocious puberty: a multicenter, randomized, parallel, controlled trial.
Wen-Jing LI ; Chun-Xiu GONG ; Mei-Jie GUO ; Jie XING ; Tang LI ; Wen-Hui SONG ; Xiao-Ping LUO ; Di WU ; Jian-Ping LIANG ; Bing-Yan CAO ; Yi GU ; Chang SU ; Xue-Jun LIANG ; Min LIU ; Rui WANG ; Feng-Ting LI
Chinese Medical Journal 2015;128(10):1314-1320
BACKGROUNDIn central precocious puberty (CPP), the pulse secretion and release of gonadotropin-releasing hormone (GnRH) are increased due to early activation of the hypothalamic-pituitary-gonadal axis, resulting in developmental abnormalities with gonadal development and appearance of secondary sexual characteristics. The CPP without organic disease is known as idiopathic CPP (ICPP). The objective of the study was to evaluate the clinical efficacy and safety of domestic leuprorelin (GnRH analog) in girls with ICPP.
METHODSA total of 236 girls with ICPP diagnosed from April 2012 to January 2014 were selected and were randomized into two groups. One hundred fifty-seven girls in the test group were treated with domestic leuprorelin acetate, 79 girls in the control group were treated with imported leuprorelin acetate. They all were treated and observed for 6 months. After 6-month treatment, the percentage of children with peak luteinizing hormone (LH) ≤3.3 U/L, the percentage of children with peak LH/peak follicle stimulating hormone (FSH) ratio <0.6, the improvements of secondary sexual characteristics, gonadal development and sex hormone levels, the change of growth rate of bone age (BA) and growth velocity, and drug adverse effects between two groups were compared.
RESULTSAfter the treatment, the percentage of children with a suppressed LH response to GnRH, defined as a peak LH ≤3.3 U/L, at 6 months in test and control groups were 96.80% and 96.20%, respectively, and the percentage of children with peak LH/FSH ratio ≤0.6 at 6 months in test and control groups were 93.60% and 93.70%, respectively. The sizes of breast, uterus and ovary of children and the levels of estradiol (E 2 ) were significantly reduced, and the growth rate of BA was also reduced. All the differences between pre- and post-treatment in each group were statistically significant (P < 0. 05), but the differences of the parameters between two groups were not significant (P > 0.05).
CONCLUSIONSDomestic leuprorelin is effective and safe in the treatment of Chinese girls with ICPP. Its effectiveness and safety are comparable with imported leuprorelin.
Body Height ; drug effects ; Body Weight ; drug effects ; Child ; Child, Preschool ; Female ; Follicle Stimulating Hormone ; blood ; Gonadotropin-Releasing Hormone ; blood ; Humans ; Leuprolide ; adverse effects ; therapeutic use ; Luteinizing Hormone ; blood ; Puberty, Precocious ; blood ; drug therapy ; Treatment Outcome
8.Treatment of premenopausal patients with advanced or recurrent breast cancer by chemical ablation.
Qiang SUN ; Han-yuan HUANG ; Yi-dong ZHOU ; Feng MAO ; Yue-qing YANG ; Ying XING
Acta Academiae Medicinae Sinicae 2003;25(1):60-62
OBJECTIVETo evaluate the clinical efficacy and safety of luteinizing hormone releasing hormone (LH-RH) analog in premenopausal patients with advanced or recurrent breast cancer.
METHODSLH-RH analog (enantone 3.75 mg/2 ml) were administered to 28 premenopausal patients with advanced recurrent breast cancer and its efficacy and side effect were observed.
RESULTSThe response rate (complete response and partial response) was 42.9%, and after 8 weeks of treatment, the plasma estrogen in all patients decreased to the level of postmenopause. No major adverse events were observed.
CONCLUSIONSLH-RH analog is effective and safe for premenopausal breast cancer with low adverse reaction and its administration method is easy.
Adult ; Breast Neoplasms ; blood ; drug therapy ; Estrogens ; blood ; Female ; Gonadotropin-Releasing Hormone ; antagonists & inhibitors ; Humans ; Leuprolide ; therapeutic use ; Luteinizing Hormone ; blood ; Middle Aged ; Neoplasm Recurrence, Local ; prevention & control ; Premenopause